Transthyretin Amyloid Cardiomyopathy Clinical Trial

Clinical Trial Finder Transthyretin Amyloid Cardiomyopathy Trials

The CARDIO-TTRansform Scintigraphy Sub-study

See Locations Near You

Summary

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

View Full Description

Full Description

Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and have had a baseline scintigraphy scan will be offered the opportunity to participate in this sub-study which involves optional scintigraphy scans.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have been properly randomized into the ION-682884-CS2 study (NCT04136171) and should have had a baseline scintigraphy scan (99mTc-DPD, 99mTc- PYP, and 99mTc-HMDP) within 12 months prior to screening for ION-682884-CS2 with planar and SPECT or SPECT/CT images that can be read by the central reader.

Exclusion criteria:

Must not meet any of the exclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).
Must not have weight or body girth that exceeds the limits of the equipment specifications.
Should not have any previously reported hypersensitivity reaction to Technetium-99m.

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

150

Study ID:

NCT06073587

Recruitment Status:

Active, not recruiting

Sponsor:

Ionis Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Columbia University Irving Medical Center
New York New York, 10032, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Cleveland Clinic Main Campus
Cleveland Ohio, 44195, United States
Oregon Health and Science University
Portland Oregon, 97239, United States
Hospital Universitario Puerta de Hierro
Majadahonda , 28222, Spain
Load More

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

150

Study ID:

NCT06073587

Recruitment Status:

Active, not recruiting

Sponsor:


Ionis Pharmaceuticals, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider